GENinCode Plc (LSE:GENI) recorded a 15% year-on-year increase in revenue to £1.6 million for the first half of 2025, supported by sales growth across the UK, European, and U.S. markets. The company maintained a solid gross profit margin of 53%, though losses widened to £2.4 million during the period.
Strategically, GENinCode is making progress in key areas: discussions with the U.S. FDA on its De Novo application are advancing, and talks continue with potential partners for test distribution across the U.S. and EU. In addition, new clinical data on its CARDIO inCode-Score was presented at major cardiology conferences, reinforcing the test’s value in evaluating cholesterol management and coronary heart disease risk.
The financial outlook remains challenging, with ongoing losses and cash flow constraints weighing on performance. Technical indicators point to bearish market sentiment, while negative earnings limit valuation appeal. Even so, recent clinical and regulatory milestones highlight strategic momentum that could support longer-term growth.
About GENinCode Plc
GENinCode is a UK-headquartered diagnostics company specializing in cardiovascular disease prevention and ovarian cancer surveillance. Operating across the UK, Europe, and the U.S., the firm delivers advanced molecular diagnostic tests, clinical algorithms, and AI-driven bioinformatics to improve risk assessment and support precision medicine.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Leave a Reply